PMID- 30891470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231006
IS  - 2333-7214 (Print)
IS  - 2333-7214 (Electronic)
IS  - 2333-7214 (Linking)
VI  - 5
DP  - 2019 Jan-Dec
TI  - Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and 
      GT4-Infected People Aged 65 Years or Older.
PG  - 2333721418817398
LID - 10.1177/2333721418817398 [doi]
LID - 2333721418817398
AB  - Background: In elderly individuals aged >/=65 years with hepatitis C virus (HCV) 
      infection, efficacious and safe HCV therapy is complicated by frequent 
      comorbidities and concomitant medications. The aim of this analysis was to 
      evaluate the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in people aged 
      >/=65 years. Methods: This is an integrated retrospective analysis of EBR/GZR 
      administered for 12 weeks in participants with HCV genotype 1 or 4 infection 
      enrolled in 12 Phase 2/3 clinical trials. The primary end point was sustained 
      virologic response 12 weeks after completing therapy (SVR12; HCV RNA below the 
      lower limit of quantification). Results: Most participants aged >/=65 years were 
      receiving >/=1 concomitant medication (322/339; 95.0%) and had >/=1 comorbidity 
      (334/339; 99%). SVR12 rates were 95.3% (323/339) in participants aged >/=65 years 
      and 95.4% (2,041/2,139) in those aged <65 years. Rates of adverse events, 
      drug-related adverse events, serious adverse events, and discontinuations were 
      similar in participants aged >/=65 years and those aged <65 years. In participants 
      aged >/=65 years, median estimated glomerular filtration rate was similar at 
      baseline and at the end of treatment. Conclusion: The efficacy and safety of 
      EBR/GZR were similar in participants with HCV infection aged >/=65 years and those 
      aged <65 years.
FAU - Flamm, Steven
AU  - Flamm S
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Peng, Cheng-Yuan
AU  - Peng CY
AUID- ORCID: 0000-0001-9030-6086
AD  - China Medical University Hospital, Taichung City.
FAU - Shibolet, Oren
AU  - Shibolet O
AD  - Tel-Aviv Medical Center, Tel-Aviv, Israel.
FAU - Nahass, Ronald
AU  - Nahass R
AD  - ID Care, Hillsborough, NJ, USA.
FAU - Hwang, Peggy
AU  - Hwang P
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Barr, Eliav
AU  - Barr E
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Robertson, Michael N
AU  - Robertson MN
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Haber, Barbara A
AU  - Haber BA
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20190122
PL  - United States
TA  - Gerontol Geriatr Med
JT  - Gerontology & geriatric medicine
JID - 101662571
PMC - PMC6415929
OTO - NOTNLM
OT  - mortality
OT  - quality of life
OT  - therapy
OT  - veterans
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: S.F. is a consultant for and has served on speakers' 
      bureaus for AbbVie, Gilead, and Merck Sharp & Dohme Corp., a subsidiary of Merck 
      & Co., Inc. R.N. received fees from Merck Sharp & Dohme Corp., a subsidiary of 
      Merck & Co., Inc., for the conduct of this study and has received fees from 
      Gilead and Janssen for the conduct of clinical trials. C-Y.P. has served as an 
      advisory committee member for AbbVie, BMS, Gilead, and MSD. O.S. has received 
      grants from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and 
      AbbVie and has received personal fees from Merck Sharp & Dohme Corp., a 
      subsidiary of Merck & Co., Inc., AbbVie, Gilead, and Neopharm. P.H., B.H., 
      M.N.R., and E.B. are employees of and hold stock in Merck Sharp & Dohme Corp., a 
      subsidiary of Merck & Co., Inc.
EDAT- 2019/03/21 06:00
MHDA- 2019/03/21 06:01
PMCR- 2019/01/22
CRDT- 2019/03/21 06:00
PHST- 2018/07/26 00:00 [received]
PHST- 2018/11/13 00:00 [revised]
PHST- 2018/11/13 00:00 [accepted]
PHST- 2019/03/21 06:00 [entrez]
PHST- 2019/03/21 06:00 [pubmed]
PHST- 2019/03/21 06:01 [medline]
PHST- 2019/01/22 00:00 [pmc-release]
AID - 10.1177_2333721418817398 [pii]
AID - 10.1177/2333721418817398 [doi]
PST - epublish
SO  - Gerontol Geriatr Med. 2019 Jan 22;5:2333721418817398. doi: 
      10.1177/2333721418817398. eCollection 2019 Jan-Dec.